Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Zimran

Showing results (191-200 of 238) with videos related to

Pageof 24
Sort By:
Internal Medicine Journal|July 26, 2023
Rapid home therapy infusion of velaglucerase alfa in naïve patients with Gaucher diseaseMichal Becker-Cohen, Shoshana Revel-Vilk, Dafna Frydman, et al.
Orphanet Journal of Rare Diseases|April 22, 2015
Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot studyEtty Osher, Aviva Fattal-Valevski, Liora Sagie, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 7, 2009
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1Gregory A Grabowski, Katherine Kacena, J Alexander Cole, et al.
American Journal of Hematology|April 2, 2024
A 10-year follow-up of high-dose ambroxol treatment combined with enzyme replacement therapy for neuropathic Gaucher diseaseSoojin Hwang, Hyunwoo Bae, Ji-Hee Yoon, et al.
Journal of Clinical Medicine|September 28, 2023
Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort StudyShoshana Revel-Vilk, Royston Mansfield, Neta Feder-Krengel, et al.
Journal of Clinical Medicine|August 26, 2023
A Deep-Learning Approach to Spleen Volume Estimation in Patients with Gaucher DiseaseIdo Azuri, Ameer Wattad, Keren Peri-Hanania, et al.
The Journal of Clinical Investigation|October 2, 2015
Proof-of-principle rapid noninvasive prenatal diagnosis of autosomal recessive founder mutationsDavid A Zeevi, Gheona Altarescu, Ariella Weinberg-Shukron, et al.
American Journal of Hematology|March 18, 2015
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher diseaseDeborah Elstein, Atul Mehta, Derralynn A Hughes, et al.
British Journal of Haematology|July 6, 2021
Experts' views on COVID-19 vaccination and the impact of the pandemic on patients with Gaucher diseaseUri Hamiel, Alina Kurolap, Ian J Cohen, et al.
Blood Cells, Molecules & Diseases|August 9, 2016
Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher diseaseAri Zimran, Gloria Durán, Pilar Giraldo, et al.
Pageof 24

Showing results (191-200 of 238) with videos related to

Sort By:
Pageof 24
Internal Medicine Journal|July 26, 2023
Rapid home therapy infusion of velaglucerase alfa in naïve patients with Gaucher diseaseMichal Becker-Cohen, Shoshana Revel-Vilk, Dafna Frydman, et al.
Orphanet Journal of Rare Diseases|April 22, 2015
Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot studyEtty Osher, Aviva Fattal-Valevski, Liora Sagie, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 7, 2009
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1Gregory A Grabowski, Katherine Kacena, J Alexander Cole, et al.
American Journal of Hematology|April 2, 2024
A 10-year follow-up of high-dose ambroxol treatment combined with enzyme replacement therapy for neuropathic Gaucher diseaseSoojin Hwang, Hyunwoo Bae, Ji-Hee Yoon, et al.
Journal of Clinical Medicine|September 28, 2023
Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort StudyShoshana Revel-Vilk, Royston Mansfield, Neta Feder-Krengel, et al.
Journal of Clinical Medicine|August 26, 2023
A Deep-Learning Approach to Spleen Volume Estimation in Patients with Gaucher DiseaseIdo Azuri, Ameer Wattad, Keren Peri-Hanania, et al.
The Journal of Clinical Investigation|October 2, 2015
Proof-of-principle rapid noninvasive prenatal diagnosis of autosomal recessive founder mutationsDavid A Zeevi, Gheona Altarescu, Ariella Weinberg-Shukron, et al.
American Journal of Hematology|March 18, 2015
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher diseaseDeborah Elstein, Atul Mehta, Derralynn A Hughes, et al.
British Journal of Haematology|July 6, 2021
Experts' views on COVID-19 vaccination and the impact of the pandemic on patients with Gaucher diseaseUri Hamiel, Alina Kurolap, Ian J Cohen, et al.
Blood Cells, Molecules & Diseases|August 9, 2016
Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher diseaseAri Zimran, Gloria Durán, Pilar Giraldo, et al.
Pageof 24